Importantly, silencing of IGF2BP2 markedly downregulated endogenous levels of ARHGAP5‐AS1 in HCC cells (all p < 0.05) (Figure 1L,M). This evidence concerns the gene IGF2BP2 and hepatocellular carcinoma.